NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors With Losses in Excess of $100k to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, of the September 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Novo Nordisk, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiffs must file a motion with the court by September 30, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Allegations Against Novo Nordisk - The lawsuit alleges that Novo Nordisk provided misleading statements about its growth potential while concealing material adverse facts [4] - It is claimed that the company overstated its ability to penetrate the GLP-1 market and the likelihood of patients switching to its branded alternatives [4]